CRL · Charles River Laboratories International, Inc.
$215.752026-07-21Sector: Healthcare; Industry: Medical - Diagnostics & Research; Sub-Industry: Life Sciences Tools & Services
Intrinsic Value Range Comparison · Mulya.ai
Very High Uncertainty
Base · active
$42
-80.6% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($37 · $289) Analysts Range ($192 · $220) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q1 | $4.1B | — | 14.9% | 17.9% | $507MM | −$180MM | $326MM | 9.9% | — | 8.5% | $6.0B | $9.70 | — |
| 2024.Q4 | $4.1B | 0.0% | 14.9% | 45.0% | $339MM | $93MM | $432MM | 10.9% | — | 5.9% | $5.5B | $9.70 | — |
| 2025.Q1 | $4.0B | -1.9% | 5.6% | 45.0% | $125MM | $215MM | $340MM | 11.4% | — | 2.3% | $5.5B | $0.21 | — |
| 2025.Q4 | $4.0B | 0.0% | 5.6% | 0.0% | $325MM | $217MM | $542MM | 13.4% | — | 5.9% | $5.6B | $0.21 | — |
| 2026.Q1 | $4.0B | -0.6% | 11.8% | 0.0% | $524MM | −$362MM | $162MM | 11.2% | — | 9.6% | $5.4B | $-3.77 | 22.3 |
| italics below = DCF projection · 10yr Rev CAGR: 3.2% |
| 2027.Q1 | $3.9B | +-4.0% | 12.7% | 2.0% | $480MM | $0MM | $480MM | 10.8% | $434MM | 8.9% | $5.4B | $9.81 | 22.0 |
| 2028.Q1 | $4.0B | +2.5% | 12.5% | 4.0% | $474MM | −$2MM | $472MM | 10.5% | $385MM | 8.8% | $5.4B | $9.68 | 22.3 |
| 2029.Q1 | $4.1B | +4.3% | 10.9% | 6.0% | $422MM | −$7MM | $414MM | 10.3% | $307MM | 7.8% | $5.4B | $8.61 | 25.1 |
| 2030.Q1 | $4.3B | +4.3% | 15.0% | 8.0% | $593MM | $0MM | $594MM | 10.1% | $399MM | 10.9% | $5.4B | $12.13 | 17.8 |
| 2031.Q1 | $4.5B | +4.2% | 15.0% | 10.0% | $606MM | $0MM | $605MM | 9.9% | $370MM | 11.2% | $5.4B | $12.37 | 17.4 |
|
| Term. Yr+ | $5.7B | 4.1% | 19.6% | 20.0% | $896MM | −$425MM | $471MM | 8.6% | $4.1B | 8.7% | — | — | — |
Active scenario IV: $42 (-80.6% vs market)